Industryweek 2518 Gsk Building

GSK Clinches $3 Billion Takeover of Human Genome Sciences

July 16, 2012
Price represents a premium of 99% to the HGS closing share price on April 18, 2012, which was the last day of trading before the informal bid was disclosed.

After increasing its bid to $3.0 billion British drugmaker GlaxoSmithKline (IW1000/88) on Monday clinched a takeover of US research partner Human Genome Sciences Inc.

GSK said that it has won the approval of HGS management after lifting its bid to $14.25 per share in cash, from the previous level of from $13 per share.

"The transaction values HGS at approximately US$3.6 billion on an equity basis, or approximately US$3.0 billion net of cash and debt."

GSK had launched a $2.6-billion hostile bid in May after HGS rejected an informal approach the previous month.

Monday's agreed bid represents a premium of 99% to the HGS closing share price on April 18, 2012, which was the last day of trading before the informal bid was disclosed.

Copyright Agence France-Presse, 2012

Popular Sponsored Recommendations

How Manufacturers Can Optimize Operations with Weather Intelligence

Nov. 2, 2023
The bad news? Severe weather has emerged as one of the biggest threats to continuity and safety in manufacturing. The good news? The intelligence solutions that build weather ...

Beware Extreme Software

Sept. 24, 2023
As a manufacturer, you understand the importance of staying ahead of the curve and being proactive in your approach to technology. With the rapid pace of change in the industry...

You Cannot Stay Competitive by Bolting New Technologies to a Legacy ERP

Oct. 20, 2023
Read this white paper to understand the benefits of shifting to a next-generation ERP system as part of a DOP.

Gain a competitive edge with real-world lessons on private 5G networks

Nov. 16, 2023
The use of private networks in manufacturing applications is rapidly growing. In this paper, we present valuable insights and lessons learned from the field with the goal of enhancing...

Voice your opinion!

To join the conversation, and become an exclusive member of IndustryWeek, create an account today!